Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer

Documenti analoghi

• Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
  di: Ali Alkan, et al.
  Pubblicazione: (2021-09-01)
• The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
  di: Tony Wu, et al.
  Pubblicazione: (2016-12-01)
• Oral mucositis with abiraterone acetate: A therapeutic dilemma
  di: Shaunak Valame, et al.
  Pubblicazione: (2020-01-01)
• Effectiveness and safety of abiraterone acetate in metastatic castration-sensitive prostate cancer patients of Western Odisha
  di: Sanjay Kumar Mahapatra, et al.
  Pubblicazione: (2024-08-01)
• Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
  di: Yoshinori Yanai, et al.
  Pubblicazione: (2019-07-01)